ICU-SLEEP: Investigation of Sleep in the Intensive Care Unit
Study Details
Study Description
Brief Summary
Sleep deprivation is common and severe in critically ill patients cared for in intensive care units (ICUs), and is hypothesized to be a key modifiable risk factor for delirium and long-term cognitive disability. Dexmedetomidine reduces the incidence of delirium in ICU patients by unknown mechanisms. This project will determine whether dexmedetomidine reduces delirium by improving sleep, whether bolus dosing vs continuous infusion is better, and the relationship of sleep quality to long-term cognitive outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
Sleep deprivation is among the most common complaints about the ICU experience. ICU sleep tends to be light and non-restorative (as opposed to deep / restorative sleep), severely fragmented, and distributed throughout the day and night rather than consolidated into nighttime hours. Sleep deprived patients suffer from sleep debt, a condition of impaired attention and memory, and cognitive slowing. Sleep disturbances in the ICU arise not only from light and noise pollution, but also from drugs that interfere with brain activity involved in restorative sleep. Sleep deprivation has also been suggested as a major modifiable risk factors for acute encephalopathy, also known as delirium. Delirium is an acute state of confusion that affects up to 80% of ICU patients, and is one of six leading causes of preventable morbidity and mortality in hospitalized elderly patients. Many patients who survive delirium experience long-term cognitive impairment and loss of independence. Current medications used in the ICU to treat sleep problems (e.g. benzodiazepines, antipsychotics) do not induce natural sleep and do not prevent delirium. In contrast, the investigators have found that the α2-adrenoceptor agonist dexmedetomidine can induce biomimetic sleep, a brain state whose pattern of electroencephalogram (EEG) activity, cerebral blood flow, and functional connectivity approximates restorative sleep. Moreover, a recent large clinical trial in post-surgical patients suggests that low-dose dexmedetomidine given overnight substantially reduces the risk of delirium. It is unknown whether this benefit is linked to improved sleep, or whether patients with better sleep while in the ICU have better long-term cognitive outcomes. The investigator's central hypothesis is that sleep deprivation substantially mediates both the short- and long-term cognitive impairments associated with delirium in critical illness. To test this hypothesis, this study is designed to systematically determine 1) the impact of prophylactic dexmedetomidine on sleep quality, 2) the optimal way to give dexmedetomidine (all night vs at the beginning of the night only), 2) the impact of sleep deprivation on short-term cognitive function and delirium, and 3) the contribution of sleep deprivation to long-term neuropsychiatric outcome following critical illness. At the conclusion of these studies, the investigators will have expanded knowledge of sleep physiology in critical illness and relationship of sleep with delirium; evaluated a new preemptive therapeutic strategy to promote sleep and prevent delirium, and developed an understanding of how sleep impacts neuropsychological outcomes after critical illness. These studies will thus will provide crucial guidance for individualized approaches to preserving long-term brain health in this vulnerable patient population.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Dexmedetomidine (Dex) very-low dose group Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows: 1) Group 1: Dex at 0.1 mcg/kg/h from 8PM until 7AM |
Drug: Dexmedetomidine
See description of study arms
|
| Active Comparator: Dexmedetomidine (Dex) low dose group Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows: 2) Group 2: NS at 0.3 mcg/kg/h from 8PM until 7AM |
Drug: Dexmedetomidine
See description of study arms
|
| Placebo Comparator: Usual care + placebo group Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows: 3) Group 3: NS at 0.075 ml/kg/h from 8PM until 7AM. |
Drug: Dexmedetomidine
See description of study arms
|
Outcome Measures
Primary Outcome Measures
- Incidence of delirium [7 days]
incidence of delirium, defined as any positive CAM or CAM-ICU assessment over the first 7 ICU days (Aim 1a), comparing usual care+placebo (n=250) with Dex (combined slow-bolus + low-dose overnight continuous infusion groups, n=500)
Secondary Outcome Measures
- Incidence of delirium between Dex groups [7 days]
Incidence of delirium within the two Dex treatment subgroups within the first 7 days within the ICU, assessed by the Confusion Assessment Method (CAM) or CAM-ICU.
Eligibility Criteria
Criteria
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Admitted to MGH Blake 7 or 12, or Elllison 4 ICU at Massachusetts General Hospital.
-
Male or female, aged > 50 years
-
Provision of signed and dated informed consent form (by patient or LAR)
-
Stated willingness to comply with all study procedures and availability for the duration of the study.
-
Not on mechanical ventilation at the time of enrollment.
-
Able to be enrolled before 7PM.
-
For females of reproductive potential: pregnancy test is negative.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Unable to be assessed for delirium (e.g. blindness or deafness)
-
Pregnancy or lactation
-
Known allergic reactions to components of dexmedetomidine
-
Follow-up would be difficult (e.g. active substance abuse, homelessness)
-
Severe dementia, as measured by a score of ≥3.3 on the Short Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
-
Known pre-existing neurologic disease or injury with focal neurologic or cognitive deficits
-
Serious cardiac disease (e.g. sick sinus syndrome, sinus bradycardia, second or third degree AV block, congestive heart failure with ejection fraction < 30%)
-
Severe liver dysfunction (Child-Pugh class C)
-
Severe renal dysfunction (receiving dialysis)
-
Low likelihood of survival >24 hours
-
Low likelihood of staying in ICU overnight
-
Patient is receiving either of the anticholinergic drugs scopolamine or penehyclidine
-
Concomitant enrollment in another study protocol that may interfere with data acquisition or reliability of measurements;
-
Deemed unsuitable for selection by the research team or ICU providers due to any medical, legal, social, language (non-English speaking) or interpersonal issues that would either compromise the study or the routine care of patients.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
Sponsors and Collaborators
- Massachusetts General Hospital
- National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
- Principal Investigator: M. Brandon Westover, MD/PhD, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2017P000090